



Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Date Published: Tuesday, 1 Oct 2024

DETAILED NEWS

SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference at 2:30 PM ET on Monday, October 7, 2024. A live webcast of the fireside chat will be available in the Investors & Media Section of Sagimet's website at www.sagimet.com, with an archived replay available following the live event. Inducement Grants In connection with the hiring of four employees, the Compensation Committee of Sagimet's Board of Directors approved inducement grants of stock options to purchase shares of the Company's Series A common stock with a total aggregate value of \$611,000, as determined based on the Black Scholes value on October 1, 2024, to be granted on October 1, 2024 to the four newly-hired employees.

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with Sagimet. The options will have an exercise price equal to the closing price of Sagimet's Series A common stock as reported by the Nasdaq Global Market on October 1, 2024.

The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the date in which the applicable employee's employment commenced) and the remaining shares vesting monthly over 36 months thereafter, subject to each individual's continued service with Sagimet through the applicable vesting dates. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate.

Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH.

➤ FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results.

➤ For additional information about Sagimet, please visit www.sagimet.com. About MASH MASH is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe.

➤ In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH.

➤ Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver.

➤ The goal of the name change was to establish an affirmative, non-stigmatizing name and diagnosis. Forward-Looking Statements This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995.

➤ All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet's clinical development plans and related anticipated development milestones, Sagimet's cash and financial resources and expected cash runway.

➤ These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

➤ In some cases, these statements can be identified by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions.

➤ Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations.

➤ These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet's control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet's ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines, including its Phase 3 denifanstat program; Sagimet's relationship with Asclethis, and the success of its development efforts for denifanstat; the accuracy of Sagimet's estimates regarding its capital requirements; and Sagimet's ability to maintain and successfully enforce a adequate intellectual property protection.

➤ These and other risks and uncertainties are described more fully in the "Risk Factors" section of Sagimet's most recent filings with the Securities and Exchange Commission and available at www.sec.gov.

- ↪ You should not rely on these forward-looking statements as predictions of future events.
- ↪ The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements.
- ↪ Moreover, Sagimet operates in a dynamic industry and economy.
- ↪ New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face.
- ↪ Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Joyce Allaire Life Sci Advisors Jallaire@lifesciadvisors.com Source: Sagimet Biosciences Inc.

KEY HIGHLIGHTS

- ↪ Sagimet Biosciences Inc. (Nasdaq: SGMT) announced its participation in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference on October 7, 2024.
- ↪ The webcast will be available on the company's website.
- ↪ The company has approved inducement grants of stock options to four newly-hired employees.
- ↪ The stock options have a total aggregate value of \$611,000 and will be granted on October 1, 2024.
- ↪ The options have a ten-year term and vest over four years.
- ↪ Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors to target dysfunctional metabolic pathways.
- ↪ Their lead drug candidate, denifanstat, is in development for the treatment of MASH, a severe liver disease.
- ↪ MASH affects more than 115 million people globally.
- ↪ There is only one approved treatment in the United States, and none in Europe.
- ↪ In 2023, the name of non-alcoholic fatty liver disease (NAFLD) was changed to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH to establish a non-stigmatizing name and diagnosis.
- ↪ This press release contains forward-looking statements about Sagimet's clinical development plans, anticipated development milestones, and financial resources.

- ↳ These statements are subject to risks, uncertainties, and other factors that may affect Sagimet's business, financial condition, and results of operations.

INSIGHTS

- ↳ Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company that develops fatty acid synthase (FASN) inhibitors, will participate in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference on October 7, 2024.
- ↳ The webcast of the chat will be available live and as a replay on the company's website.
- ↳ Sagimet has hired four new employees and awarded them stock options to purchase shares of the company's Series A common stock, with a total aggregate value of \$611,000.
- ↳ These options will vest over a four-year period, subject to their continued employment with the company.
- ↳ Sagimet's lead drug candidate, denifanstat, is an oral pill in development for the treatment of MASH (metabolic dysfunction-associated steatotic liver disease).
- ↳ FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH, was successfully completed with positive results.
- ↳ MASH is a severe liver disease affecting more than 115 million people worldwide, with only one approved treatment in the US and none in Europe.
- ↳ The disease was formerly known as non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
- ↳ Sagimet's forward-looking statements include expectations of presenting data from ongoing clinical trials, anticipated development milestones, and financial forecasts.
- ↳ However, these statements are subject to risks and uncertainties, such as the company's ability to complete clinical trials within anticipated timelines, maintain and enforce intellectual property protection, and the potential for new risk factors in the dynamic industry and economy.

CONFERENCE/WEBINAR/SUMMIT

- ↳ Event Title: H.C. Wainwright 8th Annual MASH Virtual Conference Date: 2:30 PM ET on Monday, October 7, 2024

